Today's Best Stocks: Visa, Mastercard, or Comcast?
Credit card giant Visa (V) proved its strength once again. After posting quarterly results, it is forecasting strong double-digit revenue growth in fiscal year 2025. It is expanding partnerships and has value-added services to fuel its business growth.Visa posted Q1/2025 net revenue of $9.5 billion (+10% Y/Y). Earnings per share increased by 14%. The firm benefited from global payment volume growth (+9%). In addition, cross-border volumes increased by 16%.Mastercard (MA) is also a strong credit card cash machine for investors. The company increased its revenue by 15.4% Y/Y to $7.5 billion. Gross dollar volume increased by 12%. The EPS growth of over 20% is impressive. Investors who do not have a position in MA stock should consider it the best holding for 2025.In the media sector, Comcast (CMCSA) plunged to a fresh low last week. The company revealed troubles in its broadband business, where the customer count fell by 139,000 to 31.8 million. Still, Comcast blamed Hurricanes Milton and Helene for the weak performance.Video customers declined in the quarter, falling by 311,000. Cable TV markets continue to struggle. However, Peacock's revenue topped $1.3 billion (+28% Y/Y).CMCSA stock is not the best stock but is a hold. The dividend hike of $0.08, to $1.32 per share annually, would appeal to income investors.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


